ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Key Stats

• Today's Range: $4.82 to $4.93
• 50-Day Range: $4.78 to $5.48
• 52-Week Range: $3.34 to $5.82
• Volume: 12,836 shs
• Average Volume: 18,928 shs
• Market Capitalization: $43.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ImmuCell Stock Analysis - MarketRank™

ImmuCell scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ImmuCell.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmuCell is -9.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmuCell is -9.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmuCell has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.30% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently decreased by 6.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmuCell does not currently pay a dividend.

Dividend Growth

ImmuCell does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.30% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently decreased by 6.56%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for ImmuCell this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmuCell insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of ImmuCell is held by insiders.

Percentage Held by Institutions

Only 13.47% of the stock of ImmuCell is held by institutions.

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed this year?

ImmuCell's stock was trading at $5.15 at the beginning of the year. Since then, ICCC stock has decreased by 5.8% and is now trading at $4.85.
View the best growth stocks for 2025 here.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) announced its quarterly earnings results on Tuesday, February, 25th. The biotechnology company reported $0.06 EPS for the quarter. The biotechnology company earned $7.75 million during the quarter. ImmuCell had a negative trailing twelve-month return on equity of 15.32% and a negative net margin of 15.99%.

Who are ImmuCell's major shareholders?

ImmuCell's top institutional shareholders include Renaissance Technologies LLC (1.54%), Cresset Asset Management LLC (1.48%), Dauntless Investment Group LLC (1.47%) and Dimensional Fund Advisors LP (0.74%).
View institutional ownership trends.

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 2/25/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,780,000.00
• Net Margins: -15.99%
• Pretax Margin: -15.96%
• Return on Equity: -15.32%
• Return on Assets: -8.81%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 3.11
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $26.49 million
• Price / Sales: 1.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.23 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 8,912,000
• Free Float: 8,324,000
• Market Cap: $43.22 million
• Optionable: Not Optionable
• Beta: 0.62